Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.

    The EU Clinical Trials Register currently displays   41008   clinical trials with a EudraCT protocol, of which   6704   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools

    < Back to search results

    Print Download

    EudraCT Number:2010-020003-73
    Sponsor's Protocol Code Number:A3921079
    National Competent Authority:Germany - BfArM
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2010-12-29
    Trial results View results
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedGermany - BfArM
    A.2EudraCT number2010-020003-73
    A.3Full title of the trial
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A One-year study to evaluate the effects and safety of CP-690,550 in
    patients with moderate to severe chronic plaque psoriasis
    A.4.1Sponsor's protocol code numberA3921079
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorPfizer Inc. 235 East 42nd Street, New York, 10017 USA
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportPfizer Inc.
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationPfizer Inc.
    B.5.2Functional name of contact pointClinical Trials.gov Call Center
    B.5.3 Address:
    B.5.3.1Street Address235 East 42nd Street
    B.5.3.2Town/ cityNew York
    B.5.3.3Post codeNY 10017
    B.5.3.4CountryUnited States
    B.5.4Telephone number+18007181021
    B.5.5Fax number+13037391119
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.2Product code CP-690,550-10
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNTofacitinib
    D.3.9.1CAS number 540737-29-9
    D.3.9.2Current sponsor codeCP-690,550-10
    D.3.9.3Other descriptive nameTofacitinib
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number5
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D. cell therapy medicinal product No
    D. therapy medical product No
    D. Engineered Product No
    D. ATIMP (i.e. one involving a medical device) No
    D. on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboFilm-coated tablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Chronic Plaque Psoriasis
    E.1.1.1Medical condition in easily understood language
    Ulcerative colitis
    E.1.1.2Therapeutic area Diseases [C] - Immune System Diseases [C20]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 14.1
    E.1.2Level PT
    E.1.2Classification code 10037153
    E.1.2Term Psoriasis
    E.1.2System Organ Class 10040785 - Skin and subcutaneous tissue disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    • To compare the efficacy of CP-690,550 (5 mg BID & 10 mg BID) versus placebo for the reduction in severity of plaque psoriasis after 16 weeks of treatment in subjects with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.
    • To evaluate safety and tolerability over 52 weeks of treatment with CP-690,550 (5 mg BID & 10 mg BID) in subjects with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.
    E.2.2Secondary objectives of the trial
    To evaluate the onset of efficacy and durability of efficacy of CP 690,550 (5 mg BID and 10 mg BID) for the reduction in severity of plaque psoriasis at various time points during 52 weeks of treatment; To evaluate the efficacy of CP 690,550 (5 mg BID and 10 mg BID) for the reduction in pruritis at various time points during 52 weeks of treatment; To evaluate the pharmacokinetics of CP 690,550 and its relationship with clinical responses (efficacy and safety) during treatment; To evaluate effects on patient reported outcome (PRO) measures during 52 weeks of treatment with CP 690,550 (5 mg BID and 10 mg BID) at various time points in subjects with moderate to severe chronic plaque psoriasis who are candidates for systemic or photo therapy.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Subjects must meet all of the following inclusion criteria to be eligible for enrolment into the study: 1. Evidence of a personally signed and dated informed consent document indicating the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the trial. 2. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. 3. Be at least 18 years of age at time of informed consent. 4. Have had a diagnosis of plaque type psoriasis (psoriasis vulgaris) for at least 12 months prior to first dose of study drug. 5. Have a PASI score of 12 or greater AND a PGA score of 3 (“moderate”) or 4 (“severe”) at Baseline. 6. Have plaque type psoriasis covering at least 10% of total body surface area Baseline. 7. Considered by investigator to be a candidate for systemic therapy or phototherapy of psoriasis (either naïve or history of previous treatment).8. Sexually active women of childbearing potential are required to use adequate contraceptive methods during study participation. 9. No evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis (TB) as defined by all of the following: - A negative QuantiFERON® TB Gold (QFT G) In Tube test performed at or within 3 months prior to a given Screening visit. If QFT-G testing is unavailable or indeterminate upon retest, a Mantoux Purified Protein Derivative (PPD) tuberculin skin test can be performed at or within the 3 months prior to Screening.[Subjects with a history of Bacille Calmette Guérin (BCG) vaccination will be tested with the QFT G test.], Chest radiographs, taken at or within the 3 months prior to a given Screening visit, without changes suggestive of active TB infection as determined by a qualified radiologist; No history of either untreated or inadequately treated latent or active TB infection; If a subject has previously received an adequate course of therapy for either latent (9 months of isoniazid in a locale where rates of primary multi drug TB resistance are <5% or an acceptable alternative regimen) or active (acceptable multi drug regimen) TB infection, neither a QFT G test nor a PPD test need be obtained, but chest radiographs must still be obtained if not performed within 3 months prior to a given Screening visit. Documentation of adequate treatment for TB will be obtained prior to first dose of study drug; A subject who is currently being treated for active TB infection is to be excluded;A subject who is currently being treated for latent TB infection can only be enrolled with confirmation of current incidence rates of multi drug resistant TB infection in the locale, documentation of an adequate treatment regimen, and with prior approval by the Sponsor.10. Must agree to avoid prolonged exposure to the sun and avoid use of tanning booths or other ultraviolet light sources during the study. 11. Non-prohibited concomitant medications, must be on a stable regimen, which is defined as not starting a new drug or changing dosage within 7 days or 5 half lives (whichever is longer) prior to first dose of study drug. Subject must be willing to stay on a stable regimen. 12. If received any of the following treatment regimens, for any reason, are eligible providing the following minimum washout criteria are observed; Must be discontinued for at least 12 weeks prior to first dose of study drug: a.Any investigational or experimental therapy or procedure for psoriasis, psoriatic arthritis or rheumatoid arthritis; Exception: Investigational biologics should be discussed with the Pfizer Medical Monitor (or designee) to confirm period of discontinuation required
    b. Ustekinumab (Stelara®). Must be discontinued for at least 8 weeks prior to first dose of study drug: a. Adalimumab (Humira®); b. Infliximab (Remicade®); c. Alefacept (Amevive®). Must be discontinued for at least 4 weeks prior to first dose of study drug: a. Etanercept (Enbrel®); b. Systemic treatments other than biologics that could affect psoriasis, eg, oral or injectable (eg, intraarticular, intramuscular, or intravenous) corticosteroids, retinoids, methotrexate, cyclosporine, fumaric acid derivatives, sulfasalazine, hydroxycarbamide (hydroxyurea), azathioprine, intramuscular gold; c. Psoralens + UVA phototherapy (PUVA). Must be discontinued for at least 2 weeks prior to first dose of study drug: a. Topical treatments that could affect psoriasis, eg, corticosteroids, tars, keratolytics, anthralin, vitamin D analogs, and retinoids; Exceptions – the following topical treatments are allowed: non medicated emollients for use over the whole body; low or least potent (Class 6 or 7) topical corticosteroids for the palms, soles, face, and intertriginous areas only; tar and salicylic acid preparations for the scalp only, and shampoos free of corticosteroids for the scalp only, B. UVB (narrowband or broadband) phototherapy. Prior treatment with efalizumab (Raptiva®) is exclusionary.
    E.4Principal exclusion criteria
    1.Currently have non-plaque forms of psoriasis, eg, erythrodermic, guttate, pustular; nail psoriasis is allowed. 2.Have skin conditions that would interfere with evaluation of psoriasis. 3.Have drug-induced new onset or exacerbation of psoriasis from beta blockers, calcium channel blockers, antimalarial drugs or lithium.4.Have planned initiation of or changes to concomitant medication that could affect psoriasis (eg, beta blockers, calcium channel blockers, antimalarial drugs or lithium) within 2 weeks prior to randomization or during the study. 5.Cannot stop systemic, topical or photo (UVB or PUVA) therapies for psoriasis. 6.Require oral or injectable corticosteroids for any condition. 7.The following laboratory values during Screening visit(s):a. Hemoglobin <11.0g/dL or hematocrit <30%; b.White blood cell count <3.0x10 to power of 9/L (<3000/mm3); c.Absolute neutrophil count of <1.5x10 to power of 9/L (<1500/mm3); d.Platelet count <100x10 to power of 9/L (<100,000/mm3);e. Estimated creatinine clearance <40 mL/min based on the Cockcroft Gault calculation or serum creatinine more than 1.5XULN; Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) values more than 2XULN; g.Any uncontrolled clinically significant laboratory abnormality that would affect interpretation of study data or the subject’s participation in the study. 8.Women who are pregnant, lactating, or planning pregnancy while enrolled. 9.Have current or recent history of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, metabolic, endocrine, pulmonary, cardiovascular, or neurological disease. 10. Have a history of any lymphoproliferative disorder, lymphoma, leukemia or signs and symptoms suggestive of current lymphatic disease. 11.Had a single episode of disseminated herpes zoster or disseminated herpes simplex or a recurrent localized, dermatomal herpes zoster. 12.Had infection requiring hospitalization, parenteral antimicrobial therapy or as otherwise judged clinically significant by the investigator within 6 months prior to first dose of study drug. 13.Had infection requiring antimicrobial therapy within 2 weeks prior to first dose of study drug. 14.Vaccinated with live or attenuated live vaccine within the 6 weeks prior to the first dose of study drug or expects to be vaccinated with these vaccines during treatment or within the 6 weeks following the last dose of study drug. 15.Any prior treatment with non B cell-specific lymphocyte depleting agents/therapies. Subjects who received rituximab or other selective B-lymphocyte depleting agents (including experimental agents) are eligible if they have not received such therapy for at least 1 year prior to first dose of study drug and have normal CD19/20+ counts by FACS analysis. 16.Have previously been treated with efalizumab 17.Previously participated in any study of CP-690,550. 18.Have any condition possibly affecting oral drug absorption eg, gastrectomy, clinically significant diabetic gastroenteropathy or certain types of bariatric surgery such as gastric bypass. 19.Have a history of alcohol or substance abuse unless in full remission for greater than 6 months prior to first dose of study drug. 20.Have a Screening or Baseline12 lead ECG with clinically relevant abnormalities which may affect subject safety or interpretation of study results. 21.Have a known immunodeficiency disorder or a first degree relative with a hereditary immunodeficiency. 22.Have any malignancies or a history of malignancies, except adequately treated or excised non metastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in situ. 23.Have had significant trauma or major surgery within 1 month prior to Screening. 24.Require treatment with prohibited concomitant medication(s) or have received a prohibited concomitant medication within 7 days or 5 half lives (which ever is longer) prior to the first dose of study drug. 25.Known to be infected with human immunodeficiency virus (HIV), hepatitis B or hepatitis C viruses. 26.Have participated in other studies using an investigational therapy or procedure within 4 weeks or 5 half lives (whichever is longer) prior to the first dose of study drug. Any investigational therapy/ procedure for psoriasis, psoriatic arthritis or rheumatoid arthritis must be discontinued for at least 12 weeks prior to first dose of study drug. Subjects cannot participate in studies of other investigational therapies or procedures at any time during their participation in this study. 27.Have any other severe medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration. 28.Subjects who are investigational site staff members or who are Pfizer employees directly involved in the conduct of the trial. 29.In the opinion of the investigator or Pfizer medical monitor, will be uncooperative or unable to comply with study procedures.
    E.5 End points
    E.5.1Primary end point(s)
    Primary Efficacy Endpoints
    • Physician’s Global Assessment response, ie, the proportion of subjects achieving a PGA of “clear” or “almost clear”, at Week 16.
    • Psoriasis Area & Severity Index 75 response, ie, the proportion of subjects achieving at least a 75% reduction in PASI relative to baseline at Week 16.

    Safety Endpoints
    • Incidence and severity of adverse events over 52 weeks of treatment.
    • Incidence of clinical laboratory abnormalities & change from baseline in clinical laboratory values over 52 weeks of treatment.
    • Incidence of clinically significant changes in physical examination from baseline over 52 weeks of treatment.
    • Incidence of vital sign (blood pressure & heart rate) abnormalities & change from baseline in vital sign measures over 52 weeks of treatment.
    • Incidence of electrocardiogram (ECG) abnormalities & change from baseline in ECG measurements over 52 weeks of treatment.
    • Summary of adjudicated cardiovascular endpoints.
    • Summary of central laboratory pathologist over read of malignancy events.

    Pharmacokinetic Endpoints
    • Oral clearance (CL/F) & other PK parameters calculated from plasma CP-690,550 concentrations.

    Exploratory Endpoints
    •The Molecular Profiling Supplement describes potential exploratory endpoints.
    E.5.1.1Timepoint(s) of evaluation of this end point
    Week 16 and Week 52
    E.5.2Secondary end point(s)
    - PGA response at Week 4.
    - PASI75 response at Week 4.
    - PASI50 response at Week 2.
    - Change from baseline in Itch Severity Item (ISI) score at Week 16.
    - Change from baseline in Dermatology Life Quality Index (DLQI) total score at Week 16.
    - Change from baseline in ISI score at Week 2.
    - Change from baseline in DLQI total score at Week 4.
    E.5.2.1Timepoint(s) of evaluation of this end point
    Week 52
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic Yes
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E. trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial3
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned12
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA32
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    End of Trial in a Member State of the European Union is defined as the time at which it is deemed that sufficient subjects have been recruited and completed the study as stated in the regulatory application (ie, Clinical Study Application (CTA)) and ethics application in the Member State. Poor recruitment (recruiting less than the anticipated number in the CTA) by a Member State is not a reason for premature termination but is considered a normal conclusion to the study in that Member State.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months1
    E.8.9.1In the Member State concerned days14
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months1
    E.8.9.2In all countries concerned by the trial days28
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 660
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 165
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation Yes
    F.3.3.6Subjects incapable of giving consent personally Yes
    F. of subjects incapable of giving consent
    Legally acceptable representative can give consent
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state120
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 342
    F.4.2.2In the whole clinical trial 826
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Randomized and study drug treated subjects who discontinue from the study may be eligible for study A3921061, a long-term, open-label safety study, if that study is being conducted at the study site. Eligibility requirements are provided in the A3921061 protocol.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2011-01-21
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2011-03-31
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2013-04-24
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2021 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice